Materialise N.V.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a MTLS research report →
Range $10 – $10
Price Chart
About the company
Materialise N. V. (MTLS), founded in 1990 and headquartered in Leuven, Belgium, is a global leader in additive manufacturing and medical technology.
- CEO
- Brigitte de Vet-Veithen
- IPO
- 2014
- Employees
- 2,556
- HQ
- Leuven, VL, BE
Get TickerSpark's AI analysis on MTLS
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $352.00M
- P/E
- 26.14
- Fwd P/E
- 33.52
- PEG
- 0.14
- P/S
- 1.23
- P/B
- 1.29
- EV/EBITDA
- 9.00
- Div Yield
- 0.00%
- Gross Margin
- 57.43%
- Op Margin
- 2.71%
- Net Margin
- 4.65%
- ROE
- 4.97%
- ROIC
- 2.12%
Latest fiscal year · YoY change
- Revenue
- $257.07M-3.6%
- Gross Profit
- $146.91M-2.6%
- Op Income
- $4.94M
- Net Income
- $7.41M-44.8%
- EPS
- $0.13-43.5%
- OCF Growth
- -27.9%
- FCF Growth
- +79.9%
- 52W High
- $8.82
- 52W Low
- $4.78
- 50D MA
- $7.73
- 200D MA
- $6.47
- Beta
- 1.30
- RSI (14)
- 33
- Avg Volume
- 204.98K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Materialise posted modest top-line growth in Q3 2026, with medical leading, manufacturing improving on a divestiture-adjusted basis, software still pressured, and full-year guidance reaffirmed.· October 28, 2026
- Consolidated Q3 revenue rose to EUR 67.7 million, with medical up nearly 10% year over year and manufacturing improving to 1.5% growth excluding divestitures.
- Gross profit was EUR 39 million and gross margin expanded to 57.7%, while adjusted EBIT was EUR 2.5 million and adjusted EBIT margin was 3.7%.
- Manufacturing series production grew by more than 30% year over year, driven by aerospace, defense, semiconductor, and general industry demand.
- Software revenue fell just over 4% to EUR 9.9 million, as cautious customer spending and longer sales cycles continued to weigh on the segment.
- The company reaffirmed full-year 2026 guidance of EUR 273 million to EUR 283 million in revenue and EUR 12 million to EUR 14 million in adjusted EBIT.
Q3 2026 consolidated revenue was EUR 67.7 million, up by more than 2% year over year; excluding the impact of recent divestitures, revenue increased by almost 5%. Gross profit was EUR 39 million, with gross margin at 57.7%, up 90 bps year over year. Adjusted EBIT was EUR 2.5 million, versus an adjusted EBIT margin of 3.7%, and net profit was EUR 1.4 million, or EUR 0.02 per share. On a segment basis, medical revenue rose nearly 10%, software revenue declined 4% to EUR 9.9 million, and manufacturing revenue fell 6% to EUR 21.3 million, though it grew 1.5% excluding divestitures. Full-year 2026 guidance was reaffirmed at EUR 273 million to EUR 283 million in revenue and EUR 12 million to EUR 14 million in adjusted EBIT.
Brigitte de Vet-Veithen emphasized execution across all business segments and said the company is accelerating investments where personalization and series manufacturing are gaining traction. She highlighted new medical products, new cardiac and soft tissue workflows, and CO-AM progress in software, while also pointing to stronger core manufacturing momentum and expanding adoption of Phits Dynaprint. Her tone was constructive and confident, with a repeated focus on scaling adoption, improving efficiency, and positioning the company for profitable growth.
Koen Berges said balance sheet strength and cash generation remain strategic advantages. He reported cash of EUR 153.5 million, gross debt of EUR 71 million, and net cash of EUR 82.5 million, up by almost EUR 12 million from the start of the year; operating cash flow in Q3 was nearly EUR 10 million, and year-to-date free cash flow was EUR 22.8 million, more than double the prior year. He also noted EUR 7.5 million of share buybacks in the first nine months, adjusted EBITDA of EUR 8 million in Q3, and increased R&D spending of EUR 12.8 million, up 12% year over year.
The main analyst focus was the manufacturing mix and what is driving the stronger series production trend. Management said it will not disclose the exact split between series manufacturing and prototyping, but described the business as moving toward a relatively balanced situation, with aerospace and defense, semiconductor, and general industry driving growth; ACTech also benefits from broader transportation demand. On software, management said the pressure is mainly from market conditions and extended sales cycles as CO-AM becomes more central to customer workflows, rather than a single issue like competition alone.
The quarter showed improved profitability and strong cash generation alongside clear traction in medical, where revenue grew nearly 10% and several new solutions were launched. Manufacturing also improved on an underlying basis, with series production up more than 30% year over year and management describing demand as broadening beyond aerospace and defense. The reaffirmed full-year revenue and adjusted EBIT guidance suggests confidence that the business can keep investing while still delivering on targets.
Software remains a weak spot, with revenue down 4% and management citing cautious customer spending and extended sales cycles. Manufacturing still declined 6% on a reported basis because divestitures and softer prototyping demand offset the series-production gains. Management is also increasing R&D and other growth investments, which helped hold adjusted EBIT to EUR 2.5 million in the quarter despite higher gross profit.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 39.1%
- Shares Outstanding
- 58.41M
- Float Shares
- 22.86M
of shares held by institutions
63 13F filers
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Disciplined Growth Investors Inc /Mn | 1.99M | ▲ 857.05K |
| Rock Point Advisors, LLC | 928.25K | ▼ 62.62K |
| Acadian Asset Management LLC | 806.38K | ▲ 202.51K |
| Archon Capital Management LLC | 766.62K | ▲ 23.90K |
| Arrowstreet Capital, Limited Partnership | 759.18K | ▲ 282.19K |
| King Luther Capital Management Corp | 588.75K | ▼ 40.00K |
| Ark Investment Management LLC | 342.12K | ▼ 77.66K |
| Renaissance Technologies LLC | 288.80K | ▼ 7.40K |
| Citadel Advisors LLC | 246.12K | ▲ 48.49K |
| Edmond De Rothschild Holding S.A. | 195.01K | ▼ 5.00K |
| Credit Agricole S A | 141.76K | ▼ 9.00K |
| Morgan Stanley | 120.03K | ▼ 29.39K |
Held by 10 ETFs
Biggest fund positions in MTLS by dollar value.
Our MTLS coverage
Recent articles, reports, and earnings notes.
No research on MTLS yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate MTLS report →Materialise: The Turnaround Remains Elusive (Rating Downgrade)
seekingalpha.com · Nov 20
Materialise: 3 Key Takeaways for Long-Term Investors
fool.com · Nov 17
Materialise NV (MTLS) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 28
Materialise Q3 Earnings Call Highlights
marketbeat.com · Oct 28
Materialise Reports Third Quarter 2026 Results
businesswire.com · Oct 28
Materialise NV to Report Third Quarter 2026 Earnings on Wednesday, October 28, 2026
businesswire.com · Oct 16
Materialise (NASDAQ:MTLS) Shares Cross Above 50-Day Moving Average – Should You Sell?
defenseworld.net · Sep 25
Materialise (NASDAQ:MTLS) Share Price Passes Above 50-Day Moving Average – Time to Sell?
defenseworld.net · Sep 9
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.